Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Reproductive System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Reproductive System Neoplasm

Cancer Family

Reproductive System Neoplasm

CI-CAN-00000338Explore in graph →

Non-malignant3,042 active trials38 approved drugs197 evidence items

NCIt: C3674

Overview
Statistics
Survival
Genomics65
Variants & evidence197
Drugs58
Trials13672
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (625)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 551–575 of 625 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.
· Gynecol Oncol · 2006 · PMID 16487996 · validated civic_curation pubmed
A novel K-ras mutation in colorectal cancer. A case report and literature review.
· Anticancer Res · 2009 · PMID 19661358 · validated civic_curation pubmed
Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor.
· Obstet Gynecol · 2016 · PMID 26942346 · validated civic_curation pubmed
Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.
· Gynecol Oncol Rep · 2019 · PMID 30809568 · validated civic_curation pubmed
Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.
· J Pathol · 2014 · PMID 25111426 · validated civic_curation pubmed
EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.
· Front Med (Lausanne) · 2022 · PMID 35572973 · validated civic_curation pubmed
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
· Cancer Discov · 2013 · PMID 23779130 · validated civic_curation pubmed

Showing 551–575 of 625 publications

← Previous
1
…
22
23
24
25
Next →

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

· Cancer Res · 2003 · PMID 12517791 · validated civic_curation pubmed

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

· Proc Natl Acad Sci U S A · 2001 · PMID 11504908 · validated civic_curation pubmed

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

· Cancer Res · 2014 · PMID 24240700 · validated civic_curation pubmed

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.

· Br J Cancer · 2014 · PMID 25010864 · validated civic_curation pubmed

Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.

· Carcinogenesis · 2013 · PMID 23764753 · validated civic_curation pubmed

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

· Clin Cancer Res · 2017 · PMID 27663592 · validated civic_curation pubmed

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.

· Cancer Res · 2009 · PMID 19244107 · validated civic_curation pubmed

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

· Cancer Res · 2009 · PMID 19117982 · validated civic_curation pubmed

Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.

· J Clin Invest · 2024 · PMID 38687617 · validated civic_curation pubmed

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

· Cancer Cell · 2015 · PMID 25670080 · validated civic_curation pubmed

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

· Cancer Cell · 2003 · PMID 12559175 · validated civic_curation pubmed

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

· Cancer Res · 2012 · PMID 22896685 · validated civic_curation pubmed

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.

· Cancer Cell · 2015 · PMID 26096845 · validated civic_curation pubmed

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

· Cancer Cell · 2010 · PMID 20227043 · validated civic_curation pubmed

KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.

· Cancer Res · 2015 · PMID 25968887 · validated civic_curation pubmed

Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

· Clin Cancer Res · 2012 · PMID 22623731 · validated civic_curation pubmed

Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.

· Cancer Biol Ther · 2016 · PMID 26574622 · validated civic_curation pubmed

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.

· Cancer Res · 2008 · PMID 18757403 · validated civic_curation pubmed